Emil Frei

20.9k citations
272 papers · 15.8k · 6 hit papers · h-index 64

Impact in

  • Oncology top 0.1%
    • Cancer Treatment and Pharmacology
    • Neutropenia and Cancer Infections
  • Hematology top 0.2%
    • Acute Myeloid Leukemia Research
    • Hematopoietic Stem Cell Transplantation

Papers in

    • Cancer Treatment and Pharmacology 44
    • Neutropenia and Cancer Infections 22
    • Cancer therapeutics and mechanisms 23

Emil Frei

265 papers receiving 14.1k citations

Emil Frei's Hit Papers

Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer 2003 · 925 citations
9250+22+44Years since publication250500750

Peers

Emil Frei
Comparison fields: 5 of 162
  • Oncology 6.2k
  • Hematology 2.3k
  • Genetics 1.3k
  • Cancer Research 1.7k
  • Pathology and Forensic Medicine 1.7k
Replace James F. Holland with:
James F. Holland United States
Paul P. Carbone United States
Herbert M. Pinedo Netherlands
Martin M. Oken United States
Vincent T. DeVita United States
Gianni Bonadonna Italy
Peter H. Wiernik United States
John Horton United States
George P. Canellos United States
Mark N. Levine Canada
Emil Frei relative to James F. Holland United States James F. Holland's profile →
Citations per field
00.5×1.5×
James F. Holland · 1×
Citations per year

Countries citing papers authored by Emil Frei

Since Specialization
Citations

This map shows the geographic impact of Emil Frei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emil Frei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emil Frei more than expected).

Fields of papers citing papers by Emil Frei

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emil Frei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emil Frei. The network helps show where Emil Frei may publish in the future.

Co-authors

The 25 scholars most cited alongside Emil Frei, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Emil Frei Line = papers co-authored together Emil Frei links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 272 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer
Hit paper breakdown →
2003925
2
A Randomized Trial of Induction Chemotherapy plus High-Dose Radiation versus Radiation Alone in Stage III Non-Small-Cell Lung Cancer
Hit paper breakdown →
1990880
3
Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide
Hit paper breakdown →
1960864
4
Dose: A critical factor in cancer chemotherapy
Hit paper breakdown →
1980654
5
Effect of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor on Chemotherapy-Induced Myelosuppression
Hit paper breakdown →
1988538
6 1998468
7
A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil.
Hit paper breakdown →
1978414
8 1975266
9 1988251
10 1990246
11 1971242
12 1963236
13 1965209
14 1973193
15 1988190
16 1971186
17
Dose schedule and antitumor studies of arabinosyl cytosine (NSC 63878).
1969177
18
Prognostic correlations and response to treatment in advanced metastatic malignant melanoma.
1974168
19 1963167
20 1972167

About Emil Frei

Emil Frei is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Hematology and Public Health, Environmental and Occupational Health, having authored 272 papers that have together received 15.8k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (44 papers), Acute Lymphoblastic Leukemia research (36 papers), Acute Myeloid Leukemia Research (30 papers), Lung Cancer Treatments and Mutations (29 papers), Lymphoma Diagnosis and Treatment (24 papers), Cancer therapeutics and mechanisms (23 papers), Neutropenia and Cancer Infections (22 papers) and Chronic Lymphocytic Leukemia Research (20 papers). The work is most often cited by research in Oncology (6.2k citations), Hematology (2.3k citations), Genetics (1.3k citations), Cancer Research (1.7k citations) and Pathology and Forensic Medicine (1.7k citations). Emil Frei has collaborated with scholars based in United States, United Kingdom and Malaysia. Frequent co-authors include Emil J. Freireich, George P. Canellos, James K. Luce, D H Ho, Paul P. Carbone, JACQUELINE WHANG, Gerald P. Bodey, A. Rosowsky, Robert W. Carey and Lowell E. Schnipper. Their work appears in journals such as Cancer, New England Journal of Medicine, Journal of Clinical Oncology, Blood and Clinical Pharmacology & Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact